Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia

• Status: Completed
• Trial end date: 2011-08-10
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

1. Clinical diagnosis of Schizophrenia

2. No acute exacerbation of symptoms requiring hospital admission or step up care in the previous six months.

3. Not on any symptomatic treatment for cognition

Exclusion Criteria:

1. Poses a significant homicidal or suicidal risk or evidence of previous homicidal or suicidal risk.

2. Co-morbid psychiatric or significant physical illness

3. Alcohol or drug abuse or dependence.